

August 2026 Medical Drug Recommendations to EBD Commissions						
No	Drug	Treating Diagnosis	Current	Recommendation	Cost (AWP)	Impacted members
1	Aukelso (denosumab 120mg)	Bone metastases (solid tumors), hypercalcemia of malignancy	NTM	Exclude	\$2,117.65 per mL	0
2	Bilprevda (denosumab 120mg)		NTM	Exclude	\$1,191.53 per mL	0
3	Jubereq (denosumab 120mg)		NTM	Exclude	\$2,337.71 per mL	0
4	Wyost (denosumab 120mg)		EBRx PA	Exclude	\$2,264.65 per mL	0
5	Xtrenbo (denosumab 120mg)		NTM	EBRx PA	\$338.82 per mL	0
6	Bildyos (denosumab 60mg)	Osteoporosis	NTM	Exclude	\$1,012.80 per mL	0
7	Bosaya (denosumab 60mg)		NTM	Exclude	\$1,957.12 per mL	0
8	Jubbonti (denosumab 60mg)		EBRx PA	Exclude	\$1,924.96 per mL	0
9	Opsomyv (denosumab 60mg)		NTM	Exclude	\$1,170 per mL	0
10	Osvyrti (denosumab 60mg)		NTM	Exclude	\$2,160.49 per mL	0
11	Stoboclo (denosumab 60mg)		NTM	Exclude	\$2,137.99 per mL	0
12	Enoby (denosumab 60mg)		NTM	EBRx PA	\$480 per mL	0
13	Alhemo (concizumab)	Hemophilia A or B	Exclude	EBRx PA	\$21,672 per mL	0
14	Qfitlia (fitusiran)	Hemophilia A or B	Exclude	EBRx PA	\$390,846.25 per mL	0
15	Arcalyst (rilonacept)	Cryopyrin-associated periodic syndromes(CAPS), Muckle-Wells syndrome, recurrent pericarditis	EBRx PA	Exclude	\$7,547.26 per vial	0
16	Avlayah (tivedinofusp alfa-EKNM 150mg vials)	Hunter syndrome (MPS II) neurologic manifestations	NTM	Exclude	\$6,240 per vial	0
17	Blenrep (balantamab)	Multiple Myeloma	Had been Removed from the Market	EBRx PA	AWP / 28 days - \$115,200	0
18	Epi-Caine (epinephrine/lidocaine/BSS2 0.025%-0.75%)	For local anesthesia/nerve blocks	NTM	No EBRx restrictions		0
19	Exdensur (depemokimab-ULAA)	Severe eosinophilic asthma	NTM	Exclude	\$31,200 per mL	0
20	Fesilty (fibrinogen, human-CHMT)	Fibrinogen deficiency	NTM	No EBRx Restrictions	\$1.32 per vial	0

No	Drug	Treating Diagnosis	Current	Recommendation	Cost (AWP)	Impacted members
21	Letybo (letibotulinumtoxin A-WLBG)	Glabellar lines	NTM	Exclude		0
22	Loargys (pegzilarginase-NBLN)	hyperargininemia	NTM	Exclude	\$16,515.80 per week; \$858,821.60 annually	0
23	Lunsumio (mosunetuzumab)	Lymphoma	No EBRx Restrictions	PA on the IV formulation only, SC is excluded on pharmacy benefit	\$774.56 per mL	1
24	Lymphir (denileukin diftitox-XCDL)	Lymphoma	NTM	Exclude	\$4,356 per vial	0
25	Otarmeni (lunsotogene parvec-CWHA otic cell/gene therapy)	OTOF-related profound sensorineural hearing loss	NTM	Exclude	\$0	0
26	Qivigy (IVIG)	Immunodeficiency illnesses	NTM	No EBRx Restrictions	\$34.46 - 5GM/50 mL and 10GM/100mL	0
27	Rybrevant Faspro	Non-small cell lung cancer	NTM	EBRx PA	Month 1: \$59,436 Month 2+: \$29,718	0
28	Saphnelo (anifrolumab-FNIA)	Systemic lupus erythematosus	No EBRx Restrictions	Exclude IV formulation	\$2,317.50 per mL	9 (Lifetime Grandfather)
29	Vyloy (zolbetuximab)	Gastric/GEJ adenocarcinoma	EBRx PA	Exclude	100MG Vial: \$1,958.59 300MG Vial: \$5,875.78	0
30	Yartemlea (narsoplimab-wuug)	Hematopoietic stem cell transplant-associated thrombotic microangiopathy	NTM	EBRx PA	\$22,083 per mL	0
31	Avtozma (tocilizumab)	Targeted Immunomodulator	Exclude	EBRx PA	\$916.36 per inj	0

NTM = new to market, PA = Prior Authorization, OS = Overall Survival, ORR = Overall Response Rate, MCID = Minimally Important Clinical Difference, No EBRx Restrictions = coverage will fall under Health Advantage policy

PA will be managed by EBRx, If no change occurs then the drug was re-reviewed by EBRx clinical committee for new data but no change in coverage